SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is currently trending as community discourse intensifies over reports regarding Donald Trump's significant financial gains from crypto and stock trading during his presidency. Supporters and critics remain deeply divided, with discussions centering on political loyalty, accusations of market manipulation, and the broader implications of his administration's policies on national and economic affairs.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending as investors aggressively reprice the stock, driven by a 5.6% stake disclosure from BlueCrest Capital and growing momentum behind Agility Robotics as a leading U.S. humanoid robotics play. Community members are actively comparing the stock's pre-merger phase to previous high-growth SPAC successes like ASTS and OKLO, while debating the firm's commercial deployment pipeline with major partners like Amazon and NVIDIA.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending due to the company's recent strategic push into the physical AI and robotics sector, underscored by new partnerships and the recent Rev8 LiDAR platform receiving critical regulatory compliance that unlocks federal infrastructure project access. Community sentiment remains focused on the company's role as a 'picks-and-shovels' provider for autonomous systems, though discourse is split between long-term bullish conviction in its technological moat and skepticism regarding short-term volatility and past share dilution.

GE Vernova, Inc. engages in the electric power industry. It operates through the following segments: Power, Wind, and Electrification. The Power segment offers design, manufacture, and servicing gas, nuclear, hydro, and steam technologies, providing a critical foundation of dispatchable, flexible, stable, and reliable power. The Wind segment manages wind generation technologies, including onshore and offshore wind turbines and blades. The Electrification segment refers to the grid solutions, power conversion, electrification software, and solar and storage solutions technologies required for the transmission, distribution, conversion, storage, and orchestration of electricity from point of generation to point of consumption. The company was founded November 9, 2021 and is headquartered in Cambridge, MA.

GE Vernova Inc.

GE Vernova is surging as strong electrification demand and a massive order backlog fuel investor confidence in its role as a critical power infrastructure provider for AI data centers. The stock is seeing significant institutional interest and positive momentum following strong earnings, with market participants closely monitoring its strategic positioning in the grid modernization cycle.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is experiencing heightened investor activity driven by a strategic partnership with Honda and growing anticipation surrounding the upcoming World Ducati Week, where the community expects potential updates on solid-state battery testing. While some investors remain skeptical about the timeline for commercial scale and the impact of insider stock sales, bullish sentiment is fueled by the company's progress in anode-free technology and its expansion into high-growth sectors like AI data center power.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is seeing significant upward momentum as investors react to a positive delivery beat and raised annual production guidance, fueling active community debate regarding the company's ability to successfully scale its R2 platform. Market participants are closely watching the stock's ability to maintain technical support levels amidst heavy institutional volume and ongoing discussions about Rivian's long-term competitive positioning against other major EV players.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing intense volatility and downward pressure as investors rotate out of semiconductor and tech holdings due to escalating geopolitical tensions in the Middle East and concerns over stretched AI valuations. The community is actively debating whether current price levels represent a high-conviction discount buying opportunity or a deeper correction for this leveraged ETF.

Anthropic

Anthropic is trending due to reports that it is in talks with Samsung to manufacture custom AI server chips, alongside intense market attention surrounding its confidential IPO filing and ongoing government efforts to regulate its advanced Claude models. The community is actively debating the startup's rapid valuation growth, its potential IPO timeline, and the implications of its deep-pocketed infrastructure partnerships with tech giants.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is seeing significant investor attention driven by strong data from its maintenance study for rezpegaldesleukin, which demonstrated long-term durability and efficacy in atopic dermatitis patients. The community is actively debating the stock's potential for future buyouts or partnerships, while sentiment remains split between long-term bulls encouraged by the clinical progress and skeptics wary of the company's past history and recent dilution.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing significant momentum driven by a major contract award for counter-drone systems and robust backlog expansion, reinforcing its position in the rapidly evolving defense technology sector. Community discussion is heavily focused on the stock's impressive technical setup and its role within a broader rotation into autonomous defense and robotic systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Corp Appoints Andrew Gengos As CFO

(RTTNews) - Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16...

IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up

Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

Equity

The stock gained 14% in the previous session but is now on track for its steepest one-day decline since early January, if losses hold.


Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday

Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...

Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen

Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...

Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...

Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears

Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...

Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...

Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...

Immuneering (IMRX) to Release Earnings on Thursday

Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.19
Prev Close	$5.05
Open	$5.06
Dividend Yield	0.00%
50-Day Moving Average	$4.93
Beta	1.29
Avg. Volume	2.15M
PE Ratio	-4.45

52-Week High	$10.08
52-Week Low	$2.90
Market Capitalization	$326.72M
EPS (Annual)	-$1.27
Price to Book	1.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMRXImmuneering Corp

Latest IMRX News